MRNS Quote, Financials, Valuation and Earnings

Singular Genomics Systems has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of -4136.7%. Marinus Pharmaceuticals's return on equity of -1150.43% beat Singular Genomics Systems's return on equity of -54.24%.

Marinus Pharmaceuticals has a consensus price target of $1.07, signalling upside risk potential of 98.64%. On the other hand Singular Genomics Systems has an analysts' consensus of -- which suggests that it could fall by -36.55%. Given that Marinus Pharmaceuticals has higher upside potential than Singular Genomics Systems, analysts believe Marinus Pharmaceuticals is more attractive than Singular Genomics Systems.

Marinus Pharmaceuticals has a beta of 1.035, which suggesting that the stock is 3.471% more volatile than S&P 500. In comparison Singular Genomics Systems has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Singular Genomics Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Singular Genomics Systems pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Singular Genomics Systems quarterly revenues of $406K. Marinus Pharmaceuticals's net income of -$24.2M is lower than Singular Genomics Systems's net income of -$16.8M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Singular Genomics Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.97x versus 18.27x for Singular Genomics Systems. Usually stocks with elevated PS ratios are considered overvalued.

Rocket Pharmaceuticals has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of --. Marinus Pharmaceuticals's return on equity of -1150.43% beat Rocket Pharmaceuticals's return on equity of --.

Marinus Pharmaceuticals has a consensus price target of $1.07, signalling upside risk potential of 98.64%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $43.13 which suggests that it could grow by 287.19%. Given that Rocket Pharmaceuticals has higher upside potential than Marinus Pharmaceuticals, analysts believe Rocket Pharmaceuticals is more attractive than Marinus Pharmaceuticals.

Marinus Pharmaceuticals has a beta of 1.035, which suggesting that the stock is 3.471% more volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 1.007, suggesting its more volatile than the S&P 500 by 0.72700000000001%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Marinus Pharmaceuticals's net income of -$24.2M is higher than Rocket Pharmaceuticals's net income of -$66.7M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.97x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Traws Pharma has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of -14868.42%. Marinus Pharmaceuticals's return on equity of -1150.43% beat Traws Pharma's return on equity of -124.39%.

Marinus Pharmaceuticals has a consensus price target of $1.07, signalling upside risk potential of 98.64%. On the other hand Traws Pharma has an analysts' consensus of -- which suggests that it could fall by -25.56%. Given that Marinus Pharmaceuticals has higher upside potential than Traws Pharma, analysts believe Marinus Pharmaceuticals is more attractive than Traws Pharma.

Marinus Pharmaceuticals has a beta of 1.035, which suggesting that the stock is 3.471% more volatile than S&P 500. In comparison Traws Pharma has a beta of 1.132, suggesting its more volatile than the S&P 500 by 13.246%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Traws Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Traws Pharma pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Traws Pharma quarterly revenues of $57K. Marinus Pharmaceuticals's net income of -$24.2M is lower than Traws Pharma's net income of -$8.5M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Traws Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.97x versus 32.60x for Traws Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -283.63% compared to Marinus Pharmaceuticals's net margin of --. Marinus Pharmaceuticals's return on equity of -1150.43% beat Viking Therapeutics's return on equity of --.

Marinus Pharmaceuticals has a consensus price target of $1.07, signalling upside risk potential of 98.64%. On the other hand Viking Therapeutics has an analysts' consensus of $110.00 which suggests that it could grow by 179.83%. Given that Viking Therapeutics has higher upside potential than Marinus Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Marinus Pharmaceuticals.

Marinus Pharmaceuticals has a beta of 1.035, which suggesting that the stock is 3.471% more volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.344%.

Marinus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Marinus Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Marinus Pharmaceuticals quarterly revenues are $8.5M, which are larger than Viking Therapeutics quarterly revenues of --. Marinus Pharmaceuticals's net income of -$24.2M is higher than Viking Therapeutics's net income of -$24.9M. Notably, Marinus Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Marinus Pharmaceuticals is 0.97x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.